Introduction
============

Schizophrenia is a severe neuropsychiatric mental disorder caused by inherent dysfunction of the brain, occurs in about 1% of the population, and is characterized by hallucinations, delusions, and thinking or speech disturbances. Schizophrenia presents positive symptoms such as auditory hallucination, mood abnormality, lack of insight into the illness delusions, and initial vagueness in speech, whereas the negative symptoms present emotional apathy, lack of drive, and social withdrawal.[@b1-ndt-11-1067]

Functional and structural disconnectivities are among the most reproducible neurophysiological abnormalities associated with schizophrenia and refer to macroscopic neuroanatomical dynamics and are mainly measured by diffusion-tensor imaging, tractography, volumetric magnetic resonance imaging, and magnetization-transfer imaging.[@b2-ndt-11-1067]

Neuroinflammatory mechanisms implicated in schizophrenia include glial (astroglial loss and activation, microglial activation, and priming), immunologic (cytokines, chemokines, and prostaglandins), and oxidative (reactive oxygen and nitrogen species) aberrations. These mechanisms are thought to result in glutamatergic (hypofunction) and dopaminergic (limbic hyperfunction, frontal hypofunction) dysregulations.[@b3-ndt-11-1067]

Schizophrenia can be genetic, although in many cases of identical twins, only one sibling developed schizophrenia. Another postulation is the dopamine (DA) receptor's abnormality, mainly D2 receptors. Other factors could implicate in schizophrenia such as toxins, family environment, migration, and socioeconomic factors.[@b1-ndt-11-1067]

Khat leaves (*Catha edulis* Forsk) has a stimulant effect and comes from West Asia and countries bordering the Red Sea in east coast Africa. Khat is traditionally consumed by keeping the slowly chewed leaves in the side of the cheek, releasing the Khat active constituents, and swallowing with saliva.[@b4-ndt-11-1067],[@b5-ndt-11-1067]

High consumption of Khat resulted in a state resembling paranoid schizophrenia or maniac behavior. A short-lived schizophrenic from psychotic illness and mania due to excessive khat chewing was documented presenting psychotic paranoid delusions and manic-like psychosis.[@b6-ndt-11-1067]--[@b10-ndt-11-1067]

Khat contains cathinone and cathine, which have sympathomimetic effects mediated through cathinone-induced catecholamine secretion by releasing catecholamines from presynaptic storage sites, and inhibit catecholamines reuptake and also monoamine oxidase enzyme (MAO). These amines include DA and serotonin.[@b11-ndt-11-1067] Khat may have also MAO inhibiting action.[@b12-ndt-11-1067]

DA or β-(3,4-dihydroxyphenyl)ethylamine is an endogenous neurotransmitter catecholamine transmitting signals between neurons that are separated by a synaptic cleft.[@b13-ndt-11-1067] Serotonin (5-hydroxytryptamine \[5-HT\]) is an indolamine monoamine neurotransmitter in the central nervous system (CNS), mainly in the basal ganglia and limbic system.[@b14-ndt-11-1067],[@b15-ndt-11-1067]

Khat psychostimulant activity is mediated through release of DA and 5-HT.[@b16-ndt-11-1067] The metabolism of serotonin is primarily done by MAO. The principle metabolite of serotonin is hydroxyindoleacetic acid (HIAA).[@b17-ndt-11-1067]

Intermittent oral administration of *C. edulis* extract (200 mg/kg) induces DOPAC significant reduction with increment of urinary catecholamine (HVA) indicating amine oxidase activity inhibition.[@b4-ndt-11-1067],[@b18-ndt-11-1067],[@b19-ndt-11-1067]

Khat effect is due to DA release rather than 5-HT release.[@b16-ndt-11-1067],[@b20-ndt-11-1067] Cathinone (beta-keto analog of amphetamine) is the main psychoactive alkaloid of fresh khat leaves and has indirect sympathomimetic mechanism through modulating the release of catecholamines, mainly DA from storage sites in the synaptic terminal, and indirectly affects electrolyte balance by increasing copper and calcium and decreasing zinc plasma concentrations. Cathinone (−) isomer is approximately three times more potent than (+) isomer at DA terminals in the CNS.[@b12-ndt-11-1067],[@b20-ndt-11-1067]--[@b23-ndt-11-1067]

It was reported that cathinone may act on noradrenaline transporters.[@b24-ndt-11-1067] Schizophrenia is treated by neuroleptic drugs, which have an antipsychotic effect; haloperidol drug binds preferentially to D2 and Alpha 1 receptors at low dose (ED50 =0.13 mg/kg and 0.42 mg/kg, respectively) and 5-HT2 receptors at a higher dose (ED50 =2.6 mg/kg) with pronounced DA antagonism. Haloperidol, a non-selective DA antagonist, was found to reduce cathinone-induced biting and licking movements.[@b25-ndt-11-1067] Risperidone is a second-generation antipsychotic with more pronounced serotonin antagonism than DA antagonism.[@b26-ndt-11-1067]

This study was aimed to evaluate the interference of Khat chewing with antipsychotic medications by assaying DA, serotonin, epinephrine, norepinephrine, and their related metabolites.

Patients and methods
====================

Ethical consideration
---------------------

Written consent was taken from all participants as a routine admission protocol. As the hospital is a mental and psychiatric health hospital (Al-Amal Hospital) in Sana'a, Yemen, it is a charge-free governmental hospital, and all patients were informed that their diagnosis and biological samples taking during diagnosis will be recorded and could be used anonymously for education and research purposes.

The research protocol followed all the ethical regulations stated by the scientific research ethical committee in the university. Protocol, consent format, recorded information, and sampling procedures were approved by the committee. The university and the hospital ethical regulations prohibit disclosing names and personal information of any patients without legislative procedure or applying any invasive protocol was not needed for the diagnosis such as tissue biopsy.

All our blood samples were collected during regular and routine diagnosis procedure of patients without using any invasive protocols. The authors are confirmed that they did not administer khat in purpose for the patients. Khat groups were classified by asking the patients during patient history recording as khat is a common traditional medicine and being used routinely in a widespread manner in Yemen.

Study design
------------

The current study was carried out as a case--control study. In all, 79 Yemeni male subjects were recruited (aged 39.64±0.44 years, body mass index averaged 8±1.2 kg/m^2^, and were nonsmokers), out of which 42 subjects suffered from late-onset paranoid schizophrenia. They were examined and treated during temporary remission in the psychiatric department and were classified according to their khat chewing habits into two main subgroups: either khat-chewer subgroup (SKc; n=21, *r*=11, *h*=10), patients chewed khat during treatment (when they were discharged for holidays), or non-khat-chewer subgroup (SNKc; n=21, *r*=11, *h*=10). Each subgroup further subdivided according to type of treatment into r (risperidone) and h (haloperidol). The daily doses of risperidone and haloperidol were 5 mg and 10 mg, respectively.

Healthy subjects who chewed khat and were not suffering from paranoid schizophrenia were taken as *positive controls* (HKc, n=17). Healthy subjects who did not chew khat and were not suffering from paranoid schizophrenia were taken as *negative controls* (HNKc, n=20).

All subjects (in groups HKc or SKc) were demonstrating khat chewing habits, determined as daily abuse with duration of 4--8 hours, and khat chewing habit was highly comparable within the patient groups in quantity (average 100--120 g).

Patients' inclusion criteria considered age, sex, onset of disease, previous readmission to hospital, past history of mental illness, family history of mental illness, and date of admission of each patient, while the exclusion criteria excluded dementia or mental retardation diagnosis, any intermittent therapy (on/off), and any patient exposed to severe drug side effects, shifted from one drug to another, or administered any concomitant psychotropic medications.

Sociodemographic and clinical characteristics
---------------------------------------------

On admission, all patients underwent a routine clinical interview with specialist psychiatrist to register psychotic symptoms using the rating instrument that assesses even different symptoms of schizophrenia instrument; positive and negative syndrome scale (PANSS)[@b27-ndt-11-1067] comprises three components: positive (P), negative (N), and cognitive or general psychopathology (G). Positive syndrome is composed of symptoms such as delusions, hallucinations, and disorganized thinking. Negative syndrome is characterized by deficits in cognitive, affective, and social functions, including blunting affect and passive withdrawal. General psychopathology is composed of many deficits in cognition such as disorientation, poor attention, lack of insight, and active social avoidance. Positive and negative subscales each contain seven items (P1--P7, N1--N7); General psychopathology subscale contains 16 items with the major emphasis on cognition (G1--G16). Diagnosis at discharge was given according to the *ICD-10* classification of mental and behavioral disorders.[@b28-ndt-11-1067]

Sample collection
-----------------

Venous blood samples were collected 2 hours after lunch in the HNKc group, 1 hour after treatment in the SNKc group, 1 hour after treatment and starting of continued khat chewing in SKc, and 1 hour after starting of continued khat chewing in HKc (they chewed the khat outside the hospital before coming to outpatient psychiatric department and then underwent blood drawing) using vacutainer. Blood samples were collected on EDTA tubes and immediately centrifuged at 3,500× *g* for 10 minutes, and separated plasma was divided into six separated aliquots in Eppendorf (micro centrifuge) tubes and stored at −70°C for later analysis of DA (Cat No CEA851Ge), homovanillic acid (HVA) (Cat No CED717Ge), 5-hydroxytryptamine (serotonin) (Cat No CEA808Ge), 5-HIAA (Cat No CEB005Ge), epinephrine (Cat No CEA858Ge), and norepinephrine (Cat No CEA907Ge) using ELISA kits from Cloud-Clone Corp Company (Houston, TX, USA) and following the manufacturer instructions, while 3,4-dihydroxyphenylacetic acid (DOPAC) was measured using microdialysis-HPLC as described by Dethy et al.[@b29-ndt-11-1067]

Data analysis
-------------

Data were collected and analyzed using SPSS version 15 (SPSS Inc., Chicago, IL, USA). One-way ANOVA was used to assess the difference between frequencies (the associations between khat chewing and paranoid schizophrenia). Tukey's post hoc test was used to test the difference between subgroup means, and *F* value test tested the multivariate effect of investigated subjects using multivariate Pillai's trace, Wilks' lambda, Hotelling trace, and Roy's largest root tests. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means. Pearson's chi-squared test was used to test the significant differences between PANSS scores from study baseline and after 6 weeks and 12 weeks duration; Phi and Cramer's V were used as symmetric measures to evaluate the chi-square correlation strength. Observed difference was considered to be significant at *P*\<0.05.

Results
=======

All analyzed data in the ANOVA table ([Table 1](#t1-ndt-11-1067){ref-type="table"}) and multivariate tests table ([Table 2](#t2-ndt-11-1067){ref-type="table"}) are showing highly significant correlations between groups and within groups.

Post hoc tests for all tested groups (multiple comparisons, Tukey's HSD) in [Tables 3](#t3-ndt-11-1067){ref-type="table"}[](#t4-ndt-11-1067){ref-type="table"}--[5](#t5-ndt-11-1067){ref-type="table"} show ([Figure 1A](#f1-ndt-11-1067){ref-type="fig"}) significant elevation in DA in all khat chewing groups, while SKch and SKcr groups are showing significant elevation in DA level than HKc group, exhibiting the significant positive effect of khat on DA increment in both SKch and SKcr groups. DOPAC ([Figure 1B](#f1-ndt-11-1067){ref-type="fig"}) is illustrating significant decrease in all khat chewing groups with an interesting outcome, the unexpected significant increase in SNKcr group. HVA is illustrating significant elevation in all khat chewing groups; SKch group is illustrating significant increase in HVA than SKcr group ([Figure 1C](#f1-ndt-11-1067){ref-type="fig"}).

Serotonin ([Figure 2A](#f2-ndt-11-1067){ref-type="fig"}) is illustrating significant elevation in all khat chewing groups with significant increase in both SKch and SKcr groups, and HIAA ([Figure 2B](#f2-ndt-11-1067){ref-type="fig"}) is illustrating significant elevation in all khat chewing groups with significant increase in SKch and SKcr groups.

Norepinephrine ([Figure 3A](#f3-ndt-11-1067){ref-type="fig"}) is illustrating significant elevation in all khat chewing groups with significant increase in both SKch and SKcr groups. Epinephrine ([Figure 3B](#f3-ndt-11-1067){ref-type="fig"}) is illustrating significant elevation in all chewers than non-chewers. Another interesting finding is encountered in the unexpected significant decrease in epinephrine in the SNKcr group, indicating that risperidone drug is possibly decreasing plasma epinephrine. [Table 6](#t6-ndt-11-1067){ref-type="table"} shows the improvement/deterioration in symptoms according to khat chewing within 12 weeks duration. [Table 7](#t7-ndt-11-1067){ref-type="table"} shows the sociodemographic and clinical characteristics.

Discussion
==========

In vitro studies reported that cathinone may act on noradrenaline transporters and serotonin receptors and induce motor activities and was found to have four times higher affinity than racemic amphetamine for serotonin receptors in isolated rat fundus.[@b24-ndt-11-1067],[@b30-ndt-11-1067],[@b31-ndt-11-1067]

Repeated doses of amphetamines 5 mg/kg twice daily for successive 5 days in rats induce behavioral sensitization phenomenon due to DA release.[@b32-ndt-11-1067],[@b33-ndt-11-1067]

In addition, administration of khat or cathinone to rats after unilateral lesion of substantia nigra with 6-hydroxydopamine induced ipsilateral rotation, in a similar fashion to amphetamine, suggesting that they have indirect DA-releasing actions on the CNS.[@b34-ndt-11-1067]

Several preclinical studies on rats treated with cathinone (3.2 mg/kg) showed increase in DA efflux measured by microdialysis (55%), and the behavioral effect of cathinone in animals is attributed to increasing the level of DA release or inhibiting its reuptake,[@b12-ndt-11-1067],[@b35-ndt-11-1067],[@b36-ndt-11-1067] and this might explain the khat-inducing behavioral sensitization phenomenon. Locomotor sensitization and deficits in prepulse inhibition induced by psychostimulants are two paradigms that have been widely studied as animal behavioral models of amphetamine psychosis. Repeated oral administration of a standardized *C. edulis* extract (containing a dose of 1 mg cathinone per kilogram body weight) or (−) cathinone (1.5 mg/kg) to rats induced a strong locomotor sensitization and led to a gradual deficit in prepulse inhibition.[@b4-ndt-11-1067]

Chronic administration of either the whole khat extract or cathinone in rats results in a significant depletion of DA in several brain areas, particularly on the nigrostriatal DA terminal projections,[@b4-ndt-11-1067] and exhibits the same neurotoxic effect of chronic amphetamine administration on the dopaminergic innervations of caudate, inducing their degeneration.[@b37-ndt-11-1067]

Cathinone has to penetrate to intraneuronal sites in order to evoke release, and the uptake inhibitors prevent this penetration; therefore, DA release inhibitors or pretreatment with the relatively selective dopaminergic neurotoxin 6-hydroxydopamine significantly attenuates cathinone-induced effects,[@b25-ndt-11-1067],[@b32-ndt-11-1067] while Zelger et al[@b38-ndt-11-1067] have demonstrated that pretreatment with reserpine (monoamine store depleting agent) or methyl-*p*-tyrosine (a catecholamine synthesis inhibitor) abolished locomotor and increased stereotyped behavior induced by cathinone. On the other hand, pretreatment with haloperidol, a non-selective DA antagonist, was found to reduce biting and licking movements caused by cathinone.

In vivo microdialysis in rats after acute intraperitoneal administration of cathinone, in a similar fashion to amphetamine, increased levels of DA but decreased levels of DA metabolite DOPAC in a dose-dependent manner,[@b19-ndt-11-1067] and similar to amphetamine, cathinone led to depletion of serotonin and its corresponding metabolites in both anterior and posterior striatum, which suggests that aggression in this paradigm is enhanced presumably by decreasing the level of serotonin and its metabolites.[@b34-ndt-11-1067]

In human, khat induces hypomanic illness with grandiose delusions and paranoid or schizophrenic psychosis with persecutory delusions associated with mainly auditory hallucinations, fear, and anxiety, resembling amphetamine psychosis,[@b21-ndt-11-1067],[@b39-ndt-11-1067] and induced psychotic states have been described in over 20 case reports,[@b40-ndt-11-1067] while recent community-based studies showed that khat use is associated with severe psychiatric problems.[@b41-ndt-11-1067]

There are a number of reports of psychiatric disorders secondary to khat chewing with features of manic-like psychosis[@b6-ndt-11-1067] and paranoid psychosis.[@b7-ndt-11-1067],[@b8-ndt-11-1067]

Accordingly, two cases of homicide and combined homicide and suicide have been reported following consumption of khat.[@b7-ndt-11-1067],[@b39-ndt-11-1067]

In addition to cathinone, other khat cathine alkaloid or d-norpseudoephedrine has been identified as an additional psychoactive ingredient with psychostimulant properties.[@b42-ndt-11-1067]

Khat withdrawal syndrome includes dysphoria, depression, irritability, anxiety, poor concentration, hypersomnia, fatigue, paranoia, akathisia, and drug craving.[@b43-ndt-11-1067],[@b44-ndt-11-1067]

Several investigators claim that khat use is not necessarily linked to psychological morbidity; any association that is found may reflect an interaction with other environmental factors.[@b10-ndt-11-1067]

This study's results come in agreement with all the previous studies, as schizophrenic patients khat chewing groups (SKch and SKcr) for treated patients showed significant increase in DA, DA metabolite HVA, serotonin, serotonin metabolites HIAA, epinephrine, and norepinephrine than schizophrenic patients non-khat chewing groups (SNKch and SNKcr) and control healthy groups (HNKc and HKc). This outcome was explained by khat induction release effect on both DA and serotonin through khat cathinone and cathine alkaloids.

This study revealed two interesting outcomes. The first one was the significant increase in DOPAC in the SNKcr group and was expected to show the same decrement pattern like other non-khat-chewer group, SNKch, and this outcome could be explained as risperidone treatment induced a decrement in plasma DA levels and increment in plasma DOPAC in the schizophrenic patients.[@b45-ndt-11-1067] Khat chewing in the SKcr group had compensated the induction effect of risperidone, and the DOPAC plasma level was declined. This might deeply explain the mechanism of action for risperidone through affecting DA biosynthesis and metabolism.

The second interesting outcome was the marked significant decrease in epinephrine in the SNKcr group than other groups, particularly SNKch and HNKc groups, and this could be explained as serotonin concentration dependent can increase Ca^2+^ and its effect is blocked by a broad-spectrum 5-HT antagonist (metergoline). Calcium triggers the exocytosis of chromaffin granules, releasing epinephrine into the bloodstream.[@b46-ndt-11-1067]--[@b48-ndt-11-1067] Risperidone is a 5-HT antagonist; therefore, it blocks Ca^2+^ elevation by serotonin and consequently blocks release of epinephrine into the bloodstream.

According to PANSS scores assessed at study startup, after 6 weeks, and then after 12 weeks duration ([Table 6](#t6-ndt-11-1067){ref-type="table"}), khat chewing prohibited the improvements in SKcr PANSS positive and PANSS negative and significantly deteriorated the PANSS general scale.

This study showed two limitations: we could not confirm the khat effect on SKch PANSS positive because the SNKch group showed non-significant mild improvement and the other limitation is the discontinuation of khat administration during hospitalization periods.

In conclusion, khat chewing in schizophrenic patients is contraindicated because it aggravates the disease symptoms, attenuates all used treatment medications, and deteriorates all biochemical markers of the patients.
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![Effects of khat chewing and paranoid schizophrenia on plasma level of dopamine (**A**) and its related metabolites, DOPAC (**B**) and HVA (**C**).\
**Notes:** Each value represents as mean ± SEM. \*For comparison between khat-chewers and non-chewers between groups and within groups, ^▼^for comparison between SNKch or SNKcr and HNKc, and ^⋄^for comparison between SKch or SKcr and HKc. Note that mostly rest of all other comparisons were significant. \*^,▼^*P*\<0.05; \*\**P*\<0.01; \*\*\*^,▼▼▼,⋄⋄⋄^*P*\<0.001.\
**Abbreviations:** H, healthy; N, non; K, khat; c, chewing; S, schizophrenic; h, haloperidol; r, risperidone; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; SE, standard error; SEM, standard error of the mean.](ndt-11-1067Fig1){#f1-ndt-11-1067}

![Effects of khat chewing and paranoid schizophrenia on plasma level of serotonin (**A**) and its related metabolite HIAA (**B**).\
**Notes:** Each value represents as mean ± SEM. \*For comparison between khat-chewers and non-chewers between groups and within groups, ^▼^for comparison between SNKch or SNKcr and HNKc, and ^⋄^for comparison between SKch or SKcr and HKc. Note that mostly rest of all other comparisons were significant. ^⋄^*P*\<0.05; \*\*\*^,▼▼▼,⋄⋄⋄^*P*\<0.001.\
**Abbreviations:** H, healthy; N, non; K, khat; c, chewing; S, schizophrenic; h, haloperidol; r, risperidone; HIAA, hydroxyindoleacetic acid; SE, standard error; SEM, standard error of the mean.](ndt-11-1067Fig2){#f2-ndt-11-1067}

![Effects of Khat chewing and paranoid schizophrenia on plasma level of norepinephrine (**A**), and epinephrine (**B**).\
**Notes:** Each value represents as mean ± SEM. \*For comparison between khat-chewers and non-chewers between groups and within groups, ^▼^for comparison between SNKch or SNKcr and HNKc, and ^⋄^for comparison between SKch or SKcr and HKc. Note that mostly rest of all other comparisons were significant. \*\*^,▼▼^*P*\<0.01; \*\*\*^,⋄⋄⋄^*P*\<0.001.\
**Abbreviations:** H, healthy; N, non; K, khat; c, chewing; S, schizophrenic; h, haloperidol; r, risperidone; SE, standard error; SEM, standard error of the mean.](ndt-11-1067Fig3){#f3-ndt-11-1067}

###### 

One-way ANOVA analysis showing correlation between groups and within groups

                                    Sum of squares   *df*        Mean square     *F*         *P*-value[\*](#tfn1-ndt-11-1067){ref-type="table-fn"}
  ---------------- ---------------- ---------------- ----------- --------------- ----------- -------------------------------------------------------
  Dopamine         Between groups   21,635.444       5           4,327.089       333.284     0.000
  Within groups    947.772          73               12.983                                  
  Total            22,583.215       78                                                       
  DOPAC            Between groups   26.917           5           5.383           31.271      0.000
  Within groups    12.567           73               0.172                                   
  Total            39.484           78                                                       
  HVA              Between groups   1,060.951        5           212.190         245.353     0.000
  Within groups    63.133           73               0.865                                   
  Total            1,124.084        78                                                       
  Serotonin        Between groups   140,676.456      5           28,135.291      245.065     0.000
  Within groups    8,380.961        73               114.808                                 
  Total            149,057.418      78                                                       
  HIAA             Between groups   21,429.771       5           4,285.954       91.032      0.000
  Within groups    3,436.963        73               47.082                                  
  Total            24,866.734       78                                                       
  Epinephrine      Between groups   1,879.219        5           375.844         18.000      0.000
  Within groups    1,524.224        73               20.880                                  
  Total            3,403.443        78                                                       
  Norepinephrine   Between groups   24,655,933.049   5           4,931,186.610   1,061.419   0.000
  Within groups    339,146.419      73               4,645.841                               
  Total            24,995,079.468   78                                                       

**Note:**

The mean difference is significant at the *P*\<0.05 level.

**Abbreviations:** ANOVA, analysis of variance; Sig, significance; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; HIAA, hydroxyindoleacetic acid.

###### 

Multivariate tests

                       Value     *F*         Hypothesis *df*   Error *df*   *P*-value   Partial eta squared
  -------------------- --------- ----------- ----------------- ------------ ----------- ---------------------
  Pillai's trace       2.566     10.696      35.000            355.000      0.000       0.513
  Wilks' lambda        0.001     39.703      35.000            284.273      0.000       0.775
  Hotelling trace      116.720   218.100     35.000            327.000      0.000       0.959
  Roy's largest root   110.248   1,118.228   7.000             71.000       0.000       0.991

**Notes:** Each *F* tests the multivariate effect of subject. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means.

**Abbreviation:** Sig, significance.

###### 

Effects of khat chewing and paranoid schizophrenia on plasma levels of dopamine and its related metabolites (DOPAC and HVA), in comparison with healthy non-khat-chewer subjects

  Variables          Healthy subjects (n=37)   Schizophrenic subjects (n=42)                                                                                                                                                                                                                                                                
  ------------------ ------------------------- ------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------
  Dopamine (pg/mL)   24.30±0.63                50.5±1.24[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"}    23.2±1.11                                                 19.82±0.48[▼](#tfn7-ndt-11-1067){ref-type="table-fn"}   61.3±1.25[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn11-ndt-11-1067){ref-type="table-fn"}    57.0±0.93[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn11-ndt-11-1067){ref-type="table-fn"}
  DOPAC (ng/mL)      3.0±0.10                  2.46±0.15[\*\*](#tfn10-ndt-11-1067){ref-type="table-fn"}      2.03±0.05[▼▼▼](#tfn11-ndt-11-1067){ref-type="table-fn"}   2.97±0.07                                               1.48±0.05[\*](#tfn6-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn11-ndt-11-1067){ref-type="table-fn"}         1.65±0.08[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn11-ndt-11-1067){ref-type="table-fn"}
  HVA (ng/mL)        9.29±0.17                 12.56±0.31[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"}   10.05±0.39                                                9.72±0.10                                               19.25±0.23[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn11-ndt-11-1067){ref-type="table-fn"}   17.3±0.19[\*\*\*](#tfn11-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn11-ndt-11-1067){ref-type="table-fn"}

**Notes:** Each value represents as mean ± SEM.

For comparison between khat-chewers and non-chewers between groups and within groups,

for comparison between SNKch or SNKcr and HNKc, and

for comparison between SKch or SKcr and HKc. Note that mostly rest of all other comparisons were significant.

*P*\<0.05;

*P*\<0.01;

*P*\<0.001.

**Abbreviations:** S, schizophrenic; K, khat; c, chewing; N, non; r, risperidone; h, haloperidol; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; SEM, standard error of the mean.

###### 

Effects of khat chewing and paranoid schizophrenia on plasma levels of serotonin (5-HT) and its metabolite (HIAA), in comparison with healthy non-khat-chewer subjects

  Variables                  Healthy subjects (n=37)   Schizophrenic subjects (n=42)                                                                                                                                                                                                                        
  -------------------------- ------------------------- -------------------------------------------------------------- ---------------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------
  Serotonin (5-HT) (ng/mL)   199.40±2.78               262.18±2.05[\*\*\*](#tfn17-ndt-11-1067){ref-type="table-fn"}   221.3±1.89[▼▼▼](#tfn17-ndt-11-1067){ref-type="table-fn"}   206.36±3.16   309.5±5.03[\*\*\*](#tfn17-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn17-ndt-11-1067){ref-type="table-fn"}   297.6±2.27[\*\*\*](#tfn17-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn17-ndt-11-1067){ref-type="table-fn"}
  5-HIAA (nmol/L)            58.10±1.18                85.41±1.62[\*\*\*](#tfn17-ndt-11-1067){ref-type="table-fn"}    64.3±4.19                                                  59.09±1.42    99.6±1.8[\*\*\*](#tfn17-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn17-ndt-11-1067){ref-type="table-fn"}     93.82±0.93[\*\*\*](#tfn17-ndt-11-1067){ref-type="table-fn"},[⋄](#tfn16-ndt-11-1067){ref-type="table-fn"}

**Notes:** Each value represents as mean ± SEM.

For comparison between khat-chewers and non-chewers between groups and within groups,

for comparison between SNKch or SNKcr and HNKc, and ⋄for comparison between SKch or SKcr and HKc. Note that mostly rest of all other comparisons were significant.

*P*\<0.05;

*P*\<0.001.

**Abbreviations:** 5-HT, 5-hydroxytryptamine; HIAA, hydroxyindoleacetic acid; S, schizophrenic; K, khat; c, chewing; N, non; r, risperidone; h, haloperidol; SEM, standard error of the mean.

###### 

Effects of khat chewing and paranoid schizophrenia on plasma levels of norepinephrine and epinephrine, in comparison with healthy non-khat-chewer subjects

  Variables                Healthy subjects (n=37)   Schizophrenic subjects (n=42)                                                                                                                                                                                                                            
  ------------------------ ------------------------- ----------------------------------------------------------------- ------------ ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Norepinephrine (pg/mL)   863.70±7.28               1,902.88±26.31[\*\*\*](#tfn24-ndt-11-1067){ref-type="table-fn"}   906.5±6.5    889.45±2.96                                                2,092.5±34.4[\*\*\*](#tfn24-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn24-ndt-11-1067){ref-type="table-fn"}   2,041.45±13.3[\*\*\*](#tfn24-ndt-11-1067){ref-type="table-fn"},[⋄⋄⋄](#tfn24-ndt-11-1067){ref-type="table-fn"}
  Epinephrine (pg/mL)      108.95±1.42               115.12±1.23[\*\*](#tfn23-ndt-11-1067){ref-type="table-fn"}        111.3±1.07   102.72±1.13[▼▼](#tfn23-ndt-11-1067){ref-type="table-fn"}   119.5±0.72[\*\*](#tfn23-ndt-11-1067){ref-type="table-fn"}                                                      113.45±0.64[\*\*\*](#tfn24-ndt-11-1067){ref-type="table-fn"}

**Notes:** Each value represents as mean ± SEM.

For comparison between khat-chewers and non-chewers between groups and within groups,

for comparison between SNKch or SNKcr and HNKc, and

for comparison between SKch or SKcr and HKc. Note that mostly rest of all other comparisons were significant.

*P*\<0.01;

*P*\<0.001.

**Abbreviations:** S, schizophrenic; K, khat; c, chewing; N, non; r, risperidone; h, haloperidol; SEM, standard error of the mean.

###### 

Positive, negative syndrome, and general psychopathology scales of patients with paranoid schizophrenia receiving haloperidol or risperidone across 12-week study period

  Variables                               Schizophrenic subjects (n=42)                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  --------------------------------------- ------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ----------- -------------------------------------------------------- ---------------------------------------------------------- ----------- ---------------------------------------------------------- -------------------------------------------------------- ------------ -------------------------------------------------------- ----------------------------------------------------------
  Positive (P) (M ± SEM)                  27±0.39                         25±0.39                                                    24±0.39                                                    28±0.42     25±0.23[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   23±0.44[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}     27.6±0.47   26.7±0.3                                                   26±0.29                                                  29.6±0.33    27.7±0.4                                                 27.2±0.35
  Negative (N) (M ± SEM)                  29.5±0.34                       27.2±0.29[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   24.9±0.99[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   29±0.43     27±0.44[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   24±0.44[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}     29.9±0.37   28.9±0.48                                                  29.1±0.43                                                31.18±0.44   30.9±0.31                                                29.6±0.41
  General psychopathology (G) (M ± SEM)   60.3±0.36                       55.8±0.38[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   51.8±0.38[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   60.9±0.43   56±0.35[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   50.8±0.32[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   61.5±0.37   60.2±0.44[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   58±0.42[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   59.7±0.42    57±0.31[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}   54.9±0.25[\*\*](#tfn28-ndt-11-1067){ref-type="table-fn"}

**Notes:** Each value represents as mean ± SEM.

For comparison between subjects within each group at 6 weeks or 12 weeks of treatment and baseline.

*P*\<0.05.

**Abbreviations:** S, schizophrenic; K, khat; c, chewing; N, non; r, risperidone; h, haloperidol; SEM, standard error of the mean; M, mean.

###### 

Sociodemographic and clinical characteristics

  Variables                                                           Healthy subjects (n=37)                                                                              Schizophrenic subjects (n=42)                                      
  ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------- ---------- ----------- ----------- -----------
  Age (years)                                                         38.4±92                                                                                              36.64±1.0                       39.9±1.4   40.18±0.6   42.1±0.56   43.09±0.6
  Onset of disease (paranoid schizophrenia with depression) (years)   0.0±0.0                                                                                              0.0±0.0                         1.5±0.16   2.09±0.25   3.5±0.30    3.36±0.33
  Previous readmission to hospital (times)                            0.0±0.0                                                                                              0.0±0.0                         1.6±0.16   1.54±0.15   2.5±0.16    2.54±0.15
  Family history of mental illness                                    No family history of mental and psychiatric illness for all subjects involved in the current study                                                                      
  Sex                                                                 All subjects involved in the current study were males                                                                                                                   

**Note:** Each value represents as mean ± SEM.

**Abbreviations:** S, schizophrenic; K, khat; c, chewing; N, non; r, risperidone; h, haloperidol; SEM, standard error of the mean.
